Boston Scientific ( BSX) said it plans to file the fifth and final module of its premarket application for the Taxus Express2 coronary stent system with the Food and Drug Administration later this month, and the news was helping lift the medical device maker's stock in afternoon trading.

The company said it plans to file the PMA around June 23. "Filing in June will keep us on schedule for approval as early as late this year, as we have previously indicated," the company said in a press release.

Shares of Boston Scientific were higher by $4.67, or 8.5%, to $59.66.

Another stock being helped by the news was Angiotech Pharmaceuticals ( ANPI), which has a licensing deal with Boston Scientific allowing for the use of paclitaxel and related compounds as coatings for stents. Angiotech was gaining $3.74, or 12%, to $35.14.

Boston Scientific launched the Taxus Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in February. The company hopes to launch the product in the U.S. late this year.